Lara M. Simpson

发表

Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality

Barry R. Davis, B. Davis, P. Whelton, 2015, Annals of Internal Medicine.

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

B. Davis, W. Cushman, H. Black, 2007, American heart journal.

Abstract 2734: Heart Failure with Preserved and Impaired Left Ventricular Systolic Function in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, H. Black, B. Massie, 2006 .

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, Jackson T. Wright, J. Williamson, 2002, JAMA.

Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis.

K. W. Davidson, J. Gallacher, J. Danesh, 2012, International journal of epidemiology.

Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, C. Furberg, J. Wright, 2001, Controlled clinical trials.

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Doris A Taylor, B. Byrne, D. Gordon, 2011, JAMA.

Characteristics and Long-Term Follow-Up of Participants with Peripheral Arterial Disease During ALLHAT

B. Davis, P. Whelton, Mahboob Rahman, 2014, Journal of General Internal Medicine.

Glycated hemoglobin measurement and prediction of cardiovascular disease.

J. Gallacher, J. Danesh, D. Lawlor, 2014, JAMA.

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

B. Davis, M. Pfeffer, J. Rouleau, 1999, Circulation.

Mortality and Morbidity During and After the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial

B. Davis, P. Whelton, S. Oparil, 2012, Journal of clinical hypertension.

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

Doris A Taylor, D. Gordon, T. Henry, 2012, JAMA.

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Dejian Lai, Saif Anwaruddin, Catalin Loghin, 2012, JAMA.

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

B. Davis, S. Solomon, P. Ridker, 2015, European heart journal.

Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).

J. Williamson, D. Gordon, J. Probstfield, 2009, American heart journal.

Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, W. Cushman, 2011, Circulation.

Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies

J. Gallacher, J. Danesh, O. Franco, 2018, European heart journal.

Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

B. Davis, W. Cushman, H. Black, 2008, Circulation.

Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended

Xianglin L. Du, B. Davis, J. Bettencourt, 2021, International Journal of Hypertension.

Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.

B. Davis, Jackson T. Wright, E. Soliman, 2017, Journal of the National Medical Association.

Long‐Term Follow‐Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT)

D. E. Mathis, B. Davis, J. Williamson, 2013, Journal of clinical hypertension.

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Doris A Taylor, B. Byrne, D. Gordon, 2010, Texas Heart Institute journal.

Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

B. Davis, Jackson T. Wright, P. Whelton, 2006, Hypertension.

Trial the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in Clinical Events in High-Risk Hypertensive Patients Randomly

B. Davis, W. Cushman, M. Proschan, 2006 .

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

Barry J. Davis, M. Landray, R. Collins, 2022, The Lancet.

Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults.

B. Davis, S. Juraschek, K. Mukamal, 2019, Hypertension.

The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

B. Davis, S. Oparil, W. Cushman, 2016, Hypertension.

Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).

Doris A Taylor, S. Berceli, J. Lima, 2017, Circulation.

Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.

B. Davis, P. Whelton, Mahboob Rahman, 2016, Clinical journal of the American Society of Nephrology : CJASN.

Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study

B. Davis, P. Okin, E. Soliman, 2015, American journal of hypertension.

Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients

Mohammad R. Ostovaneh, Doris A Taylor, B. Davis, 2020, JACC. CardioOncology.

Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality

B. Davis, P. Whelton, S. Oparil, 2020 .

Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults

B. Davis, S. Oparil, C. Pieper, 2020, Journal of the American Geriatrics Society.

Risk of Developing Alzheimer’s Disease and Related Dementias in ALLHAT Trial Participants Receiving Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker with 18 Years of Follow-Up

Xianglin L. Du, B. Davis, M. Osani, 2022, Journal of Alzheimer's disease & Parkinsonism.

A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial

Mohammad R. Ostovaneh, Doris A Taylor, B. Davis, 2021, European journal of heart failure.

Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, W. Cushman, 2011, Circulation.

Abstract MP72: The Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: the ALLHAT Trial

B. Davis, S. Juraschek, K. Mukamal, 2019, Circulation.

Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, W. Cushman, 2011, Circulation.

Controlled, Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells 2 to 3 Weeks after Acute Myocardial Infarction

Doris A Taylor, B. Byrne, T. Henry, 2010 .

Legacy effect of delayed blood pressure lowering drug treatment in middle-aged adults with mildly elevated blood pressure: systematic review and meta-analysis

B. Davis, C. Reid, M. Nelson, 2020, Journal of Human Hypertension.

Effect of Chlorthalidone, Amlodipine, and Lisinopril on Visit‐to‐Visit Variability of Blood Pressure: Results From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial

Barry R Davis, B. Davis, P. Whelton, 2014, Journal of clinical hypertension.

Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)

B. Davis, G. Marcus, C. Albert, 2017, Circulation. Arrhythmia and electrophysiology.

The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

B. Davis, S. Juraschek, R. Shmerling, 2020, Journal of hypertension.

Sustained SBP control and long-term nursing home admission among Medicare beneficiaries

B. Davis, S. Oparil, C. Pieper, 2021, Journal of hypertension.

Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT

B. Davis, S. Oparil, C. Pieper, 2019, Journal of clinical hypertension.

Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project

Barry R Davis, B. Davis, P. Whelton, 2009, Clinical trials.